Louisa R. Hoes
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.
Journal: Cancer discovery
Published: November 14, 2024
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).
Journal: ESMO open
Published: October 14, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 05, 2024
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 14, 2023
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Journal: The Journal of pathology
Published: October 09, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Journal: International journal of cancer
Published: February 27, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Journal: BMC cancer
Published: December 20, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 14, 2022
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
Journal: Cancer chemotherapy and pharmacology
Published: January 11, 2022
Last Updated: 09/26/2026